Search Results

You are looking at 121 - 130 of 180 items for :

  • "tamoxifen" x
  • Refine by Access: All x
Clear All
Full access

Puyao C. Li, Zilu Zhang, Angel M. Cronin, and Rinaa S. Punglia

the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group . J Clin Oncol 2006 ; 24 : 3381 – 3387 . 16801628 2. Houghton J , George WD , Cuzick J , . Radiotherapy and tamoxifen in women with completely excised ductal carcinoma

Full access

Joyce Liu and Ursula Matulonis

Carrasco EM . Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research . Gynecol Oncol 2002 ; 84 : 201 – 209 . 45. del Carmen MG Fuller AF Matulonis

Full access

Azeez Farooki

, exemestane, and letrozole) have been shown to increase the risk of fracture compared with tamoxifen. Osteoporotic fracture is a concern in men, because up to 25% of men older than 50 suffer one, he added. ADT appears to increase the risk of fracture in men

Full access

Paul C. Hendrie and David A. Garcia

cancer mortality is not known. Other factors, such as venous stasis from vessel compression, immobility, central venous catheters (CVC), and thrombogenic anticancer therapies, such as tamoxifen and thalidomide, play a role in some patients. The new agents

Full access

Julia C. Shih and Anthony J. Olszanski

. 6 Within cancer care, the earliest reports of nonadherence rates were documented in breast cancer with endocrine therapies, ranging from 12% to 59% with tamoxifen and 9% to 50% with aromatase inhibitors. 7 In a systematic review by Greer et al, 1

Full access

Kathleen Harnden and Kimberly Blackwell

%) received chemotherapy. In both Z-FAST and ZO-FAST, patients were concurrently treated with letrozole. In ABCSG-12, patients were treated with ovarian suppression and either anastrozole or tamoxifen. The AZURE patients were on a variety of standard adjuvant

Full access

Deborah J. MacDonald, Kathleen R. Blazer, and Jeffrey N. Weitzel

women who are BRCA -positive. 6 Retrospective studies of BRCA carriers indicate that adjuvant tamoxifen 7 and risk-reduction mastectomy can significantly reduce the risk for new primary breast cancer, up to 50% and 90%, respectively. 8 Risk

Full access

Suzanne C. O'Neill, Claudine Isaacs, Calvin Chao, Huei-Ting Tsai, Chunfu Liu, Bola F. Ekezue, Nandini Selvam, Larry G. Kessler, Marc D. Schwartz, Tania Lobo, and Arnold L. Potosky

Cuzick J Wale C . Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study . J Clin Oncol 2010

Full access

Mei-Chin Hsieh, Lu Zhang, Xiao-Cheng Wu, Mary B. Davidson, Michelle Loch, and Vivien W. Chen

subtypes are a key determinant. Clinical trials have demonstrated that patients with HR+ (ER+ and/or PR+) breast cancer benefit from tamoxifen, those with HR– (ER– and PR–) benefit from adjuvant chemotherapy, and those with HER2+ disease benefit from

Full access

Traci LeMasters, S. Suresh Madhavan, Usha Sambamoorthi, Hannah W. Hazard-Jenkins, Kimberly M. Kelly, and Dustin Long

. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer . N Engl J Med 2004 ; 351 : 971 – 977 . 11. Hughes KS Schnaper LA Bellon JR . Lumpectomy plus tamoxifen with or without irradiation